

### ISSUE @ A GLANCE



#### Risks and management of cardioversion and catheter ablation in atrial fibrillation

T.F. Lüscher

2999

### CardioPulse

#### KODEX-EPD mapping for AF ablation

M. Nicholls

3003

#### The National Institute for Health Research (NIHR) Global Health Research Group on Atrial Fibrillation management

G.Y.H. Lip, Y. Guo, P. Lotufo, R. Sureenthirakumaran, L. Humphreys, and G.N. Thomas, on behalf of the NIHR Global Reach AF Investigators

3005

#### Atrial Fibrillation in the Era of Emerging Cancer Therapies

A. Guha, A.K. Dey, H. Jneid, J.P. Ibarz, D. Addison, and M. Fradley

3007

#### Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA<sub>2</sub>DS<sub>2</sub>-VASC score of 1

P. Sulzgruber, S. Wassmann, A.G. Semb, W. Doehner, P. Widimsky, T. Gremmel, J.C. Kaski, G. Savarese, G.M.C. Rosano, C. Borghi, K. Kjeldsen, C. Torp-Pedersen, T.A. Schmidt, B.S. Lewis, H. Drexel, J. Tamargo, D. Atar, S. Agewall, and A. Niessner

3010

### FAST TRACK CLINICAL RESEARCH

#### Atrial fibrillation

##### Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial

S.H. Hohnloser, J. Camm, R. Cappato, H.-C. Diener, H. Heidbüchel, L. Mont, C.A. Morillo, K. Abozguia, M. Grimaldi, H. Rauer, P.-E. Reimitz, R. Smolnik, C. Mönnighoff, and J. Kautzner

3013

#### Editorial

##### Continuous anticoagulation with catheter ablation: answers and questions

S.D. Pokorney and C.B. Granger

3022

### CLINICAL RESEARCH

#### Atrial fibrillation

##### Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials

W.F. McIntyre, S.J. Connolly, J. Wang, S. Masiero, A.P. Benz, D. Conen, J.A. Wong, H. Beresh, and J.S. Healey

3026

#### Editorial

##### Cardioversion as bystander in atrial fibrillation-related thrombo-embolism


F.W.A. Verheugt

3033

**Sex-based differences in outcomes, 30-day readmissions, and costs following catheter ablation of atrial fibrillation: the United States Nationwide Readmissions Database 2010-14**

*J.W. Cheung, E.P. Cheng, X. Wu, I. Yeo, P.J. Christos, H. Kamel, S.M. Markowitz, C.F. Liu, G. Thomas, J.E. Ip, B.B. Lerman, and L.K. Kim*

3035



**Editorial**

**Peri-procedural complications in women: an alarming and consistent trend**  
*L. Wang, K.A. Selzman, and R.U. Shah*

3044


**SPECIAL ARTICLE**

**Atrial fibrillation**

**Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data**

*J.A. Singh and J.D. Cleveland*

3046



**Editorial**

**The difficult relationship between uric acid and cardiovascular disease**  
*S. Masi, N.R. Pugliese, and S. Taddei*

3055

**DISCUSSION FORUM**

**Risk stratification for stroke in atrial fibrillation: incorporating neurologists in the comprehensive management**

*H.-F. Li, B. Liang, and H.-Y. Li*

3058

**Response to: Risk stratification for stroke in atrial fibrillation: incorporating neurologists in the comprehensive management**

*A.M. Killu and B.J. Gersh*

3060

**Central autonomic network and Takotsubo cardiomyopathy: how left insular cortex interact?**  
*M. Nagai, K. Date, and M. Kato*

3061

**Neurocardiology: the brain-heart connection in Takotsubo syndrome**  
*J.R. Ghadri, R.A. Levinson, T.F. Lüscher, L. Jäncke, and C. Templin*

3062

## Recommendations for participation in competitive sport in athletes with hypertrophic cardiomyopathy:

opening the sacks of Aeolus

E.D. Pagourelas, E. Kouidi, and V.P. Vassilikos

3064

## CARDIOVASCULAR FLASHLIGHTS

An uncommon case of acute non-traumatic paraplegia: endovascular management of an occluding thrombus in the thoracic aorta 32 years after open surgery for aortic coarctation

M.O. Schmidly, M. Greutmann, R. Pfiffner, and Z. Rancic

3065

Spontaneous haemorrhage on apixaban masquerading as obstructive cholangitis after heart surgery

P.O. Myers, T. Nguyen-Tang, J. Alibegovic-Zaza, and I. Inan

3066

## CORRIGENDA

Corrigendum to: Ephemeral Coronary Heart Disease

3032

Corrigendum to: Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial

3043

Corrigendum to: Risk stratification for stroke in atrial fibrillation: incorporating neurologists in the comprehensive management

3059



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site

<https://academic.oup.com/eurheartj>



[www.eurheartj.org](http://www.eurheartj.org)